25 results
425
EX-2.1
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
from such dispositions, minus (e) costs remaining to wind down Hepion’s operations, including severance, change-in-control, retention or other … , reorganize or otherwise wind-up the business or operations of Hepion or resolve to approve any of the foregoing;
(xiv) change Hepion’s methods
8-K
EX-2.1
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
from such dispositions, minus (e) costs remaining to wind down Hepion’s operations, including severance, change-in-control, retention or other … , reorganize or otherwise wind-up the business or operations of Hepion or resolve to approve any of the foregoing;
(xiv) change Hepion’s methods
424B3
HEPA
Hepion Pharmaceuticals, Inc.
15 Jul 24
Prospectus supplement
5:17pm
. On April 19, 2024, we announced that we have begun wind-down activities in our ASCEND- NASH clinical trial.
Rencofilstat is a therapeutic drug … the desired results and we may be unsuccessful in identifying and implementing any strategic transaction.
On April 19, 2024, we announced the wind down
10-KT
futd13q48stvfn
26 Mar 18
Annual report (with FYE transition)
12:00am
424B5
n5s2c0a
7 Oct 15
Prospectus supplement for primary offering
12:00am
10-K
cqzmvmvppio 4n0v5t
29 Sep 14
Annual report
12:00am
10-12G/A
EX-99.1
fnnklb
6 Feb 14
Registration of securities (amended)
12:00am